We Take Diagnostics to the Next Level

At Ares Genetics, we develop precision diagnostics for precision medicine to improve the way infections are diagnosed and treated.

We Take Diagnostics to the Next Level

At Ares Genetics, we develop precision diagnostics for precision medicine to improve the way infections are diagnosed and treated.

News

8/8/2019

Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing

Download

4/7/2019

Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Download

12/4/2019

Ares Genetics Introduces NGS Services for Pharma and Public Health Sector at Upcoming ECCMID 2019

Download

Latest tweets

Events

Meet the Ares Team at the following events

13/12/2019

Berlin, Germany

13. Nationale Qualitätskongress Gesundheit

Go To Event Page

05/12/2019

Monthey, Switzerland

BioArk Innovation Day

Go To Event Page

18/11/2019

Graz, Austria

European Summit of Industrial Biotechnology

Go To Event Page

07/11/2019

Washington D.C., USA

World AMR Congress

Go To Event Page

04/11/2019

Mannheim, Germany

EIT Health AMR & AI Symposium

Go To Event Page

08/10/2019

London, UK

EIT Health Catapult Digital Health Semifinals

Go To Event Page

02/10/2019

Washington D.C., USA

Career

We are data scientists, bioinformaticians, microbiologists, pharmaceutical, diagnostic and commercial experts that share a vision for the next-generation of genomics-based infectious disease diagnostics & therapeutics.

Join us in taking infectious disease diagnostics to the next level!

Besides the openings listed below, we are regularly offering part- or full-time positions as well as PhD and master theses and welcome unsolicitated applications.

Senior Full Stack Developer (m/f)

for a staff function role in unlimited full-time employment at Ares Genetics in Vienna.

Press Kit

No items found.

Publications

At Ares, we pursue a partnership based, open-innovation approach with academic and industry partners and are committed to sharing our developments with the community.

Scientific Publications & Application Notes

Functional Validation of Antibiotic Resistance Markers by High-Throughput Screening

Joint Ares Genetics publication with Prof. Müller (HIPS Saarbrücken) and Prof. Keller (CCB Saarland). The study introduces a novel, universally applicable high-throughput workflow for rapid identification and functional validation of antimicrobial resistance (AMR) biomarkers from >1,000 clinical isolates. When combined in a multiplex diagnostic in silico panel, the identified AMR biomarkers reached high positive and negative predictive values of up to 97 and 99%, respectively. Additionally, we demonstrate that the developed workflow can be used to identify potential novel resistance mechanisms.

The Science of Antimicrobial Resistance

Review by Ares Genetics published in MedNous (https://www.mednous.com/) on AMR and potential solutions

Integrating Culture-based Antibiotic Resistance Profiles with Whole-genome Sequencing Data for 11,087 Clinical Isolates

Joint Ares Genetics publication with Prof. Keller’s group at Saarland University introducing GEAR-base as a standardized research resource for antibiotic resistance genotypes and phenotypes. GEAR-base was originally established in collaboration with Universität des Saarlandes and Siemens and forms the nucleus of our proprietary ARESdb now combining whole-genome sequencing data for > 35,000 isolates with quantitative antibiotic susceptibility data for >100 antibiotics..

Optimizing Plasmid Identification for Clinical Bacterial Isolates Using Next-Generation Sequencing

Joint Ares Genetics publication with Prof. Keller’s group at Saarland University assessing the heterogeneity of in silico plasmid predictions based on whole-genome-sequenced clinical isolates. The study identified a high degree of heterogeneity and variation in sensitivity and precision for plasmid identification across taxa and computational approaches. Nevertheless, existing open source tools are very valuable for investigating the plasmid-borne resistome. Building upon the peer-reviewed research findings, the proprietary ARES Technology allows for fast and optimized plasmid identification from whole-genome sequencing data.

Ares Genetics and Curetis Pharma Services

We offer a comprehensive portfolio of solutions for antimicrobial drug discovery, clinical development, and product lifecycle management. Our solutions aim at supporting data-driven target and lead prioritization, accelerating clinical trials, augmenting clinical data for regulatory submissions, and informed antimicrobial drug use for effective antibiotic stewardship post launch.

Fast and Accurate Taxonomic Identification of Clinical Bacterial Isolates Using Next-Generation Sequencing

Joint Ares Genetics publication with Prof. Keller’s group at Saarland University comparing genome versus proteome-based identification of clinical bacterial isolates. Key findings include that taxonomic identification based on the proteome (by mass spectrometry, MS-biotyping) and the genome (by next-generation sequencing, NGS) show high concordance for clinical application. While NGS successfully resolved all clinical isolates on the species level, for 12% of the cases MS-biotyping resulted in genus level classification only. Building upon the peer-reviewed research findings, ARES Technology allows for fast and accurate taxonomic identification on the species level.